N-01
|
|
|
- のぶあき やすもと
- 4 years ago
- Views:
Transcription
1 N AMY BD BBLCRYSTAL N/H 1960 BD BBLCRYSTAL N/H NeisseriaHaemophilus BD BBLCRYSTAL N/H 4-A 2-A 1-A 4-B 2-B 1-B 4-C 2-C 1-C 4-D 2-D 1-D 4-E 2-E 1-E 4-F 2-F 1-F 4-G 2-G 1-G 4-H LYSALA N--ALA-PRO-ALA ALA-ALA-PHE -AMC GLY-PRO -D- g/ L L L L N L L L L D D D
2 2-H 1-H 4-I 2-I 1-I 4-J 2-J 1-J p-n-p- -p- p-n-p- o-n-p--d- g/ D p L---p p o--d L BD BBLCRYSTAL N/H Aggregatibacter actinomycetemcomitans Aggregatibacter segnis 1 Cardiobacterium hominis 1 Eikenella corrodens Gardnerella vaginalis Aggregatibacter aphrophilus Haemophilus ducreyi Haemophilus haemoglobinophilus 1 Haemophilus haemolyticus Heamophilus influenzae Haemophilus parahaemolyticus 1 Haemophilus parainfluenzae Kingella denitrificans Kingella kingae Moraxella atlantae Moraxella catarrhalis Moraxella lacunata 1 Moraxella nonliquefaciens Moraxella osloensis Psychrobacter phenylpyruvica 1 Neisseria cinerea 1 Neisseria elongata Neisseria flavescens 1 Neisseria gonorrhoeae Neisseria lactamica Neisseria meningitidis Neisseria mucosa Neisseria sicca Neisseria subflava Neisseria weaveri 1 Oligella ureolytica 1 Oligella urethralis Pasteurella multocida Suttonella indologenes 1=BBLCRYSTAL10 2
3 2BD BBLCRYSTAL N/H 4A FCT 2A FHO 1A FPR 4B FSE 2B LYS-ALA FLA 1B FTR 4C 2C 1C 4D N--ALA-PRO-ALA ALA-ALA-PHE FPH FNS FAA FTA D FAR 1D -AMC FOR 4E FGL 2E GLY-PRO FGP 1E -D- FBG 4F SAC 2F MTT 1F CAR 4G 2G PYO MTB ph G DIS 4H RBL 2H LEV 1H p-n-p- PHC p I -p- GGL p I 1I p-n-p- o-n-p--d- PHO OPG p J URE ph J REZ 6 1J ORN ph 2 3
4 3BD BBLCRYSTAL N/H 4A FCT 2A FHO FCT FCT 1A FPR FCT FCT 4B FSE FCT FCT 2B LYS-ALA FLA FCT FCT 1B FTR FCT FCT 4C FPH FCT FCT 2C N--ALA-PRO-ALA FNS FCT FCT 1C ALA-ALA-PHE FAA FCT FCT 4D FTA FCT FCT 2D FAR FCT FCT 1D -AMC FOR FCT FCT 4E FGL FCT FCT 2E GLY-PRO FGP FCT FCT 1E -D- FBG FCT FCT 4F SAC / / 2F MTT / / 1F CAR / / 4G PYO / / 2G MTB / / 1G DIS / / 4H RBL / / 2H LEV / / 1H p-n-p- PHC 4I -p- GGL 2I p-n-p- PHO 1I o-n-p--d- OPG 4J URE / / 2J REZ / 1J ORN / 2 8 BBLCRYSTAL BBLCRYSTAL ANR, GP, RGP, N/H BD BBLCRYSTAL N/H
5 BBLCRYSTAL ANR, GP, RGP, N/H % 1.0mL # mL BBLCRYSTAL N/H 3 3 5
6 CO % 2 N/H BBLCRYSTAL 3 BBL- CRYSTAL N/H F J 2 UV A E 4A BD BBLCRYSTAL 4A A B C D E F G H I J *4A 6
7 BBLCRYSTAL BBLCRYSTAL ANR, GP, RGP, N/H mL 20 1 KCl 7.50g CaCl N BBLCRYSTAL N/H 1 CO % #3.0BBLCRYSTAL BBLCRYSTAL 5TSA 5% MTM NYCV G. vaginalis GC %BD BBLCRYSTAL Manual of Clinical Microbiology 117 1BBLCRYSTAL N/H Moraxella (Branhamella) catarrhalis ATCC BBLCRYSTAL N/H 4 BBLCRYSTAL N/H 1 2 1J BBLCRYSTAL N/H
8 4BD BBLCRYSTAL N/H 4 8 4A 2A 1A 4B 2B 1B 4C 2C 1C 4D 2D 1D 4E 2E 1E 4F 2F 1F 4G 2G 1G 4H 2H 1H 4I 2I 1I 4J 2J 1J LYS-ALA N--ALA-PRO-ALA ALA-ALA-PHE -AMC GLY-PRO -D- p-n-p- -p- p-n-p- o-n-p--d- FCT FHO FPR FSE FLA FTR FPH FNS FAA FTA FAR FOR FGL FGP FBG SAC MTT CAR PYO MTB DIS RBL LEV PHC GGL PHO OPG URE REZ ORN + v v v v + + v Moraxella (Branhamella) catarrhalis ATCC V
9 5BD BBLCRYSTAL N/H 4 9 LYS-ALA N--ALA-PRO-ALA ALA-ALA-PHE -AMC GLY-PRO -D- p-n-p- -p- p-n-p- o-n-p--d- FCT FHO FPR FSE FLA FTR FPH FNS FAA FTA FAR FOR FGL FGP FBG SAC MTT CAR PYO MTB DIS RBL LEV PHC GGL PHO OPG URE REZ ORN Haemophilus aphrophilus ATCC Neisseria lactamica ATCC Kingella denitrificans ATCC Haemophilus influenzae ATCC V
10 3N/H %BD BBLCRYSTAL N/H 95.9% BD BBLCRYSTAL N/H 1 Neisseria gonorrhoeae BBL BD BBLCRYSTAL N/H TSA, MTM, NYC, V, GC BD BBLCRYSTAL N/H BD BBLCRYSTAL N/H 1 BBLCRYSTALi ii iii 3 10
11 Balows, A., W.J. Hausler, Jr., K.L. Herrmann, H.D. Isenberg, and H.J. Shadomy (ed.) Manual of clinical microbiology, 5 th ed. American Society for Microbiology, Washington, D.C. 2Baron, E.J., L.R. Peterson, and S.M. Finegold Bailey and Scott s diagnostic microbiology, 9 th ed. Mosby- Year Book, Inc., St. Louis. 3Bronfenbrenner, J., and M.J. Schlesinger A rapid method for the identification of bacteria fermenting carbohydrates. Am. J. Public Health. 8: Cowan, S.T., and K.J. Steel Manual for the identification of medical bacteria. 2 nd ed. Cambridge University Press, Cambridge. 5Edberg, S.C., and C.M. Kontnick Comparison of -glucuronidase-based substrate systems for identification of Escherichia coli. J. Clin. Microbiol. 24: Enriquez, L.A., and N.E. Hodinka The development of a test system for the rapid differentiation of Neisseria and Haemophilus. J. Clin. Microbiol. 18: Ferguson, W.W.,and A.E. Hook, Urease activity of Proteus and Salmonella organisms. J. Lab. Clin. Med. 28: Hartman, P.A Miniaturized microbiological methods. Academic Press, New York. 9Kämpfer, P., O. Rauhoff, and W. Dott Glycosidase profiles of members of the family Enterobacteriaceae. J. Clin. Microbiol. 29: Killian, M., and P. Bulow Rapid diagnosis of Enterobacteriaceae 1: detection of bacterial glycosidases. Acta Pathol. Microbiol. Scand. Sect. B. 84: Knapp, J.S., and R.J. Rice Neisseria and Branhamella, p In P.R. Murray, E.J. Baron, M.A. Pfaller, F.C. Tenover, and R.H. Yolken (ed.), Manual of clinical microbiology, 6 th ed. American Society for Microbiology, Washington, D.C. 12MacFaddin, J.F Biochemical tests for identification of medical bacteria, 2 nd ed. Williams & Wilkins, Baltimore. 13Maddocks, J.L., and M. Greenan Rapid method for identifying bacterial enzymes. J. Clin. Pathol. 28: Manafi, M., W. Kneifel, and S. Bascomb Fluorogenic and chromogenic substrates used in bacterial diagnostics. Microbiol. Rev. 55: Mandell, G.L., R.G. Douglas, Jr. and J.E. Bennett Principles and practice of infectious diseases, 3 rd ed. Churchill Livingstone Inc., New York. 16Mangels, J.,I. Edvalson, and M. Cox Rapid identification of Bacteroides fragilis group organisms with the use of 4-methylumbelliferone derivative substrates. Clin. Infect. Dis. 16(54): Moncla, B.J., P. Braham, L.K. Rabe, and S.L. Hiller Rapid presumptive identification of black-pigmented gram-negative anaerobic bacteria by using 4-methylumbelliferone derivatives. J. Clin. Microbiol. 29: Murray, P.R., E.J. Baron, M.A. Pfaller, F.C. Tenover, and R.H. Yolken (ed.) Manual of clinical microbiology, 6 th ed. American Society for Microbiology, Washington, D.C. 11
12 BD BD TEL FAX
N-03.indd
111-245130-N-03 21400AMY00158000 20099 1 BD BBLCRYSTAL N/H BD BBLCRYSTAL N/H 4-A g/ 7--4-0.175 2-A 4-- 1.501 1-A L--7--4-1.766 4-B L--7--4-1.4935 2-B LYSALA --7--4-2.237 1-B L--7--4-2.295 4-C L--7--4-2.182
N BD BBL GP 1960 BD BBL GP BBL GP BD BBL GP 4-A 2-A -D- 1-A 4-B 2-B -D- 1-B 4-C 2-C -AMC 1-C N- - -D- 4-D 2-D -D- 1-D 4-E 2-E 1-
111-251933-N-01 200810 BD BBLGP 1960 BD BBL GPBBL GP BD BBL GP 4-A 2-A -D- 1-A 4-B 2-B -D- 1-B 4-C 2-C -AMC 1-C N---D- 4-D 2-D -D- 1-D 4-E 2-E 1-E 4-F 2-F 1-F 4-G 2-G 1-G 4-H p-n-p--d- 2-H p-n-p--d- 1-H
1BD BBLCRYSTAL RGP Aerococcus viridans Arcanobacterium pyogenes Bacillus cereus Bacillus licheniformis Bacillus megaterium Bacillus pumilus Bacillus s
111-245150-N-03 21400AMY00151000 20099 1 BD BBLCRYSTAL RGP BD BBLCRYSTAL RGP 4-A 2-A 1-A 4-B 2-B 1-B 4-C 2-C 1-C 4-D 2-D 1-D 4-E 2-E 1-E 4-F 2-F 1-F 4-G 2-G 1-G 4-H 2-H 1-H 4-I 2-I 1-I 4-J 2-J 1-J -D-
N BD BBL E/NF 1960 BD BBL E/NF BBL E/NF BD BBL E/NF 4-A 4-B 4-C 4-D 4-E 4-F 4-G 4-H 4-I 4-J 2-A p-n-p- 2-B p-n-p C p-n-p-
111-251932-N-03 200810 BD BBL E/NF 1960 BD BBL E/NFBBL E/NF BD BBL E/NF 4-A 4-B 4-C 4-D 4-E 4-F 4-G 4-H 4-I 4-J 2-A p-n-p- 2-B p-n-p--- 2-C p-n-p-- 2-D 2-E p-n-p- 2-F p-n-p- 2-G p-n-p-- 2-H p-n-p- 2-I
untitled
111-245010-N-04 21300AMY00327000 20116 2 20099 1 BD BBLCRYSTAL ANR BD BBLCRYSTAL ANR 4-A 2-A 1-A 4-B 2-B 1-B 4-C 2-C 1-C 4-D 2-D 1-D 4-E 2-E 1-E 4-F 2-F 1-F 4-G 2-G 1-G 4-H 2-H 1-H 4-I 2-I 1-I 4-J 2-J
N-03.indd
111-24514035-N-03 21300AMY00325000 20099 1 BD BBLCRYSTAL GP BD BBLCRYSTAL GP g/ 4-A 7--4-0.175 2-A -D- 4---D- 1.692 1-A L--7--4-1.7775 4-B L--7--4-2.182 2-B -D- 4---D- 1.6915 1-B L--7--4-1.4315 4-C L--7--4-2.3815
untitled
Seminal paper Anhalt JP Pioneering paper Claydon MA Kishnamurthy T Enterobacter B. cereus Routine identification paper Eigner U Seng P Cherkaoui A Saureus S. Saureus* S. Vagococcus Haemophilus Mycobacterium
untitled
111-24500035-N-05 21300AMY00324000 20116 2 20099 1 BD BBLCRYSTAL E/NF BD BBLCRYSTAL E/NF 4-A 4-B 4-C 4-D 4-E 4-F 4-G 4-H 4-I 4-J 2-A 2-B 2-C 2-D 2-E 2-F 2-G 2-H 2-I 2-J 1-A 1-B 1-C 1-D 1-E 1-F 1-G 1-H
252166_変更点.indd
Ver. 5.4 1. 0 2. PC COM PC 0-1 - 3. 5.1 Windows NT4.0/2000 MFC42.DLL MSVCRT.DLL MSVCRT40.DLL 4. MicrosoftPackage Setup.exe Setup.lst Crystal1.cab Crystal2.cab 4-2 - CLINICAL 5. - 3 - 6. ver. 5.3 E/NF Chryseobacterium
Table 1 Bacteriae to be tested (1) Gram positive cocci Coagulase positive staphylococcus Coagulase negative staphylococcus Streptococcus pneumoniae Gr
Chlamydia trachomatis Key words: chlamydial antigen, ELISA, bacteria, cross reaction, respiratory infection C. trachomatis Branhamella catarrhalis C. trachomatis C. trachomatis Chlamydia trachomatis (C.
Atlas_j060419
Hill s Atlas of Veterinary Clinical Anatomy 1 29 30 2 3 4 5 31 32 33 34 35 36 37 6 7 8 9 10 11 12 13 38 39 40 41 14 15 16 17 18 19 20 21 22 23 24 25 26 27 42 43 44 45 46 47 48 49 50 51 52 53 54 55 28 81
４月号 学会特集号 １２２２４７／１６）一般演題目次
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 48 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 49 60 61 62 63 64 65 66 67 68
Table 1.Quality control of MICs for reference strains Table 2.Antimicrobial activity of gatifloxacin against aerobic bacteria Table 4.Antimicrobial activity of gatifloxacin and other quinolones against
SBP hospitalist network.key
1 Treatment and Prophylaxis of Spontaneous Bacterial Peritonitis (1); (2), (3). (1) (2) (3) :, :, 2 Clinical Question 1 72...,.,,.,... 3. CT..,. 4? SBP? SBP. 5 Clinical Question SBP? SBP,? 6 SBP (Spontaneous
日本化学療法学会雑誌第61巻第6号
β Moraxella catarrhalis Escherichia coli Citrobacter Klebsiella pneumoniae Enterobacter cloacae Serratia marcescens Proteus Pseudomonas aeruginosa Acinetobacter Bacteroides fragilis β Haemophilus influenzae
CHEMOTHERAPY aureus 0.10, Enterococcus faecalis 3.13, Escherichia coli 0.20, Klebsiella pneumoniae, Enterobacter spp., Serratia marcescens 0.78, Prote
aureus 0.10, Enterococcus faecalis 3.13, Escherichia coli 0.20, Klebsiella pneumoniae, Enterobacter spp., Serratia marcescens 0.78, Proteus mirabilis 3.13, Proteus vulgaris 1.56, Citrobacter freundii 0.39,
炭疽菌検査マニュアル Ver.1
Bacillus anthracis 3 4 CDC 1 2 2 3 3 Bacillus anthracis 3 - PCR 10 11 11 10 12 4 11 14 12 14 13 18 1 Bacillus anthracis CDC 2 3 P3 2 3 P2 1 A 2 N95 3 4 2 1 HEPA 2 3 a 5 b c d e 3 f 4 HEPA 3 1 2 N95 3 4
1) CDCManagement of patients with suspected viral hemorrhagic fever. MMWR 198837 (No.S-3)1-15. 2) CDCUpdatemanagement of patients with suspected viral hemorrhagic fever-united States. MMWR 199544 (No.25)475-479.
第122号.indd
-1- -2- -3- 0852-36-5150 0852-36-5163-4- -5- -6- -7- 1st 1-1 1-2 1-3 1-4 1-5 -8- 2nd M2 E2 D2 J2 C2-9- 3rd M3 E3 D3 J3 C3-10- 4th M4 E4 D4 J4 C4-11- -12- M5 E5 J5 D5 C5 5th -13- -14- NEWS NEWS -15- NEWS
Key words: bacterial meningitis, Haemophilus influenzae type b, Streptococcus pneumoniae, rapid diagnosis, childhood
Key words: bacterial meningitis, Haemophilus influenzae type b, Streptococcus pneumoniae, rapid diagnosis, childhood Fig.1 Distribution of the cases with bacterial meningitis by age and pathogens Chiba
E Societe de Pathologie Infectieuse de Langue Francaise (, 1991) E Spanish Thoracic Society (1992) E American Thoracic Society (ATS : 1993. ü ù2001 ) E British Thoracic Society (1993, ü è2001 ) E Canadian
<4244CDDED8C0B0BCBDC3D1466C752E696E6464>
111-5605-N-09 400AMX00064000 01778 01597 BD TM Flu 1 1 3 4 5 BD TM BD TM 6 1Processing Reagent A FluA B FluB A FluA B FluB 3A B 4B A BD TM CF BD TM CF C B A N 1. A B 1 A B A A A C A B N BD TM BD TM 1 1..
Key words: E. coli O 157: H7, fosfomycin, verotoxin, mouse infection
Key words: E. coli O 157: H7, fosfomycin, verotoxin, mouse infection Table 1. Bacterial cell counts in feces of mice infected with Esclwrichia coli O 157: H7 NK2 before and during oral dosing with fosfomycin
Table 1 Survival rates of infected mice given antibiotic doses producing peak serum a) S. aurcus Smith Challenge dose :7 ~10 (5% mucin) CFU/mouse. LD50: 1 ~103 (5% mucin) CFU/mouse. Table 2 Survival rates
Table 1. Antibacterial activitiy of grepafloxacin and other antibiotics against clinical isolates
Table 1. Antibacterial activitiy of grepafloxacin and other antibiotics against clinical isolates Table 2-1. Summary of patients treated with grepafloxacin for respiratory infection 1) Out: outpatient,
1 見出し1，12ポ，日本語ゴシック，英語Arial，段落後は6ポの設定です
8. Page1 8. B 1 5) 6) 2099 2370 50 400 mg 19 (1) 1) (a) 78.9% 30/38 4 3 35.7% 5/14 71.4% 10/1485.7% 12/142 1 83.3% 5/63 2 1 1 1 8. Page2 (b) 2099 1897 82.4% 1562/1897 2 84.0% 1298/1545 3 2 80.4% 472/58779.0%
Table 1.Resistance criteria Fig.1.The resistance rates of piperacillin,ceftazidime, cefsulodin,imipenem,aztreonam,gentamicin,tobramycin,amikacin,isepamicin,fosfomycin and ofloxacin against 2,793 strains
日本化学療法学会雑誌第64巻第4号
β β Moraxella catarrhalisescherichia colicitrobacter Klebsiella pneumoniaeenterobacter cloacaeserratia marcescens Proteus Providencia Pseudomonas aeruginosaacinetobacter Bacteroides fragilis β β E. colik.
N-03.indd
111-245111-N-03 21300AMY00496000 2272 2181 1 2 3 4 5 1Mycobacteria Growth Indicator Tube 4,7 1,10 2OADC Enrichment 3 PANTAPANTA Antibiotic Mixture, Lyophilized B600g/ 4,7 1,10 7H9 1. 2 PANTA 1 PANTA 365nm
Key words: Legionella, urinary antigen, enzymeimmunoassay (EIA), rapid diagnosis
Key words: Legionella, urinary antigen, enzymeimmunoassay (EIA), rapid diagnosis lymerase chain reaction(pcr) EIA kit Table1 @ Reference strains used in this study Table2 @ Comparison between Biotest and
Table 1. Antimicrobial drugs using for MIC
Table 1. Antimicrobial drugs using for MIC Table 2. Susceptibilities determined with the VITEK 2 system and agar dilution reference by interpretive eategory for Staphylococcus aureus Table 3. Interpretive
b) Gram-negative bacteria Fig. 2 Sensitivity distribution of clinical isolates : E. coli Fig. 3 Sensitivity distribution of clinical isolates : Pseudomonas Fig. 1 Sensitivity distribution of clinical isolates
特殊病態下感染症における抗菌薬治験の手引き作成委員会報告書（案）
VOL.51 NO.6 JUNE 2003 JUNE 2003 9) Niederman MS et al: Guidelines for the management of adults with community-acquired pneumonia. Diagnosis, assessment of severity, antimicrobial therapy and prevention.
ISO
ISO ISO ISO(International Standardization Organization) 135 ISO CD(Committee Draft) DIS(Draft for International Standard) FDIS(Final DIS) ISO ISO23500 2004.01.13 ANSI/AAMI RD52 2004.04.13 6 2004.08.09
DNA
1 1 1. 1 2. 2 3. 2 4. 2 2 1. 2 4 5 7 2. 7 3. DNA 8 4. 10 13 Plasmodium (P. falciparum) (P. vivax) (P. malariae) P. ovale 4 40% 200 7 40 48 72 1. - 1 - 2. DNA 3 3. 1) 2) 3) 4) 4. 1 1) - 2 - 2) EDTA 1) 1
1.Streptococcus pneumoniae, Streptococcus pyogenes JC-1,S.aureus Smith,methicillin (DMPPC)- susceptible S. aureus subsp. aureus (MSSA) TR101, DMPPC-resistant S. aureus subsp. aureus (MRSA) TR102, Staphylococcus
49619, H. influenzae ATCC49247, C. jejuni ATCC 33252, C. fetus ATCC15296, B. fragilis ATCC 25285, C. soldellii ATCC9714, P. rnagnus ATCC lin (ABPC), e
Key words: MIC, agar dilution method, fastidious bacteria, Etes(R) 49619, H. influenzae ATCC49247, C. jejuni ATCC 33252, C. fetus ATCC15296, B. fragilis ATCC 25285, C. soldellii ATCC9714, P. rnagnus ATCC
77 http//www.pref.nara.jp/rinsei/bio/biotop.htm 1... 1 2... 2 3... 3 4... 4 5 1... 5 6 2... 6 7 3... 7 8 4... 8 9... 9 1... 1 11... 12 12... 14 13... 16 14... 18 15... 2 16... 22 17 1... 24 18 2... 26
2006年3月8日
18 21 1990 2004 2 2005 14 15 2004 1990 2005 2003 300 7 2 1 2005 1972 100 40 6 1972 2004 197 6,500 2004 21 59 100 65 2007 5 2005 30 1.8 535.89 348.33 187.56 2006 2006 5 1 30 1 30 46 46 1 46 1000kl 4 1 100kl
05[和]_061-078[島田](責)山.indd
![05[和]_061-078[島田](責)山.indd](/thumbs/42/23101532.jpg "05[和]_061-078[島田](責)山.indd")
1858 1919 1. 1877 10 Studies in English and American Literature, No. 45, March 2010 2010 by the Engish Literary Society of Japan Women s University 62 1 1890 23 1 2 2 3 3 1891 1 1892 6 1892 9 1893 12 4
Key words: Surfactant, Tween, Legionella
Key words: Surfactant, Tween, Legionella Fig. 1 Inhibitory Activity of Various Tween Against Legionella pneumophila Fig. 2 Inhibitory Activity of Various Tween Against Legionella bozemanii Fig. 3 Inhibitory
Table 1. Antibacterial activity of azithromycin and other agents against gram-positive anaerobic bacteria and facultative anaerobic bacteria a Facultative anaerobic bacteria. Table 2. Antibacterial activity
untitled
Quantitative Risk Assessment on the Public Health Impact of Pathogenic Vibrio parahaemolyticus in Raw Oyster 1 15 5 23 48 2 21 1 16 1 16 1 11 3 1 3 4 23 1 2 16 12 16 5 6 Hazard IdentificationExposure
0788K Aeromonas salmonicida subsp. salmonicida ATCC * 0862K Aggregatibacter aphrophilus ATCC * 0467K Aggregatibacter aphrophilus ATCC 2924
KWIK-STIK 培地性能試験用 KWIK-STIK は 単一微生物株の凍結乾燥ペレット 水和液 接種用スワブで構成されるアンプル入キットで 培地の品質管理 教育用などに適しています KWIK-STIK の微生物は参照より 4 継代以内ですので 精度管理にも適しています ラベルを剥がして 作成文書などに添付することができます 保管温度 : 2~8 KWIK-STIK セット内訳 ( 価格はお問い合わせください
Key words: Streptococcus pyogenes, Streptococcus dysgalactiae subsp. equisimilis, rapid diagnosis
Key words: Streptococcus pyogenes, Streptococcus dysgalactiae subsp. equisimilis, rapid diagnosis Table 1 Strains evaluated Table 3 Comparison of sensitivity (CFU/mL) of 8 rapid diagnostic kits for detecting
2001 Mg-Zn-Y LPSO(Long Period Stacking Order) Mg,,,. LPSO ( ), Mg, Zn,Y. Mg Zn, Y fcc( ) L1 2. LPSO Mg,., Mg L1 2, Zn,Y,, Y.,, Zn, Y Mg. Zn,Y., 926, 1
Mg-LPSO 2566 2016 3 2001 Mg-Zn-Y LPSO(Long Period Stacking Order) Mg,,,. LPSO ( ), Mg, Zn,Y. Mg Zn, Y fcc( ) L1 2. LPSO Mg,., Mg L1 2, Zn,Y,, Y.,, Zn, Y Mg. Zn,Y., 926, 1 1,.,,., 1 C 8, 2 A 9.., Zn,Y,.
Key words: Limulus amoebocyte lysate assay, Limulus lysate micro-technique procedure, Chromogenic substrate assay, Rapid detection of bacteriuria
Key words: Limulus amoebocyte lysate assay, Limulus lysate micro-technique procedure, Chromogenic substrate assay, Rapid detection of bacteriuria Fig. 1 Preparation of chromogenic substrate LAL assay on
CHEMOTHERAPY
CHEMOTHERAPY VOL.41 S-2 Laboratory and clinical evaluation of teicoplanin CHEMOTHERAPY AUG. 1993 VOL.41 S-2 Laboratory and clinical evaluation of teicoplanin Table 1. Comparative in vitro activity of teicoplanin
37, 9-14, 2017 : cefcapene piperacillin 3 CT Clostridium difficile CD vancomycin CD 7 Clostridium difficile CD CD associate
37, 9-14, 2017 : 36 2015 8 6 cefcapene piperacillin 3 CT Clostridium difficile CD vancomycin 20 1983 2016 3 CD 7 Clostridium difficile CD CD associated diarrhea : CDAD CD 1,2 PPI 3 1 36 33 2015 8 6 5 5
VOL.36 S-I CHEMOTHERAPY Tabl 1 List of healthy male volunteers
VOL.36 S-I CHEMOTHERAPY Tabl 1 List of healthy male volunteers CHEMOTHERAPY MAY 1988 Table 2 Experimental schedule of CS-807 administration and sampling of feces Table 3 Isolation of aerobic and anaerobic
CHEMOTHERAPY Methicillin-resistant S.aureus(MRSA) coccus epidermidis 105 Streptococcus pyogenes E.faecali senterococcus avium Enterococcus faecium Str
cefaclor(ccl),cefuroxime(cxm),cefixime (CFIX),cefteram(CFTM),cefdinir(CFDN) pneumoniae,streptococcus pyogenes Moraxella catarrhalis,haemophilus influenzae,escherichia coli, Klebsiella pneumoniae,proteus
untitled
i ii iii EC 1-1 1 (1) (2) 3,0005,000 3 1 Web 2 Web 1-1 3 (3) (4) 18111812 (5) (1) (2) Web 4 1-2 1 (3) (4) 1812191 (5) 5 1.1 Web 2-1 6 (1) 2-1 387 2-2 7 (2) Web 57% Web 28% 2-3 (3) 43% 56% 2 50%1 26% 2-2
Key words : R-plasmid, Urinary tract infection, E. coli Fig. 1. MIC distribution against E. coli isolated from urinary tract (366 strains) and isolation - frequencies of drug-resistant strains Table 1.
Clostridium difficile ciprofloxacin, ofloxacin, norfloxacin Bifidobacterium Lactobacillus Lactobacillus Bacteroides fragilis B. fragilis C. difficile
Clostridium difficile ciprofloxacin, ofloxacin, norfloxacin Bifidobacterium Lactobacillus Lactobacillus Bacteroides fragilis B. fragilis C. difficile Key words: temafloxacin, TA-167, Bacteroides fragilis,
表 参照文献 ( 文献 ). 185, Expert Nurse. 1211, suppl, , CNS 2000, , , , 4
研究報告 がん看護専門看護師のコンサルテーション * についての概念分析 要旨 Walker Avant2005 CNS Key words はじめに 1996 2012 3 10 795 Certified Nurse SpecialistCNSCNS 327 1 CNS 2 CNS 3 4 5 6 CNS CNS 方法 Walker Avant 7 2012 8 1 2013 2 27 連絡先
untitled
2303 16 2 9 1 14 5 31 (423) 1 (4), (6) C55H84ClN17O21S3 HCl (BLM-A2) 1487.47 11 2 1 4 104 2 14 5 31 [ ] ( ) ( ) 1. 15mg 30mg( ) 5 20mL 1 5mg( ) 2. 3 15mg 30mg( ) 5mL 1mg( ) 1mL 3. 5mg 15mg( ) 4. 1 2 1
CHEMOTHERAPY JUNE 1986
VOL. 34 S-3 CHEMOTHERAPY Fig. 1 Structural formula of L-105 CHEMOTHERAPY JUNE 1986 VOL. 34 S-3 CHEMOTHERAPY Table 1 Antibacterial spectra of L-105 against gram negative anaerobic rods Inoculum 106 cells/ml
Table 1. Antibacterial activity of cefdinir, cefixime, cefteram, cefuroxime, cefaclor and amoxicillin against standard strains Inoculum size: 108 cells/ml CFDN: cefdinir, CFIX: cefixime, CFTM: cefteram,
CHEMOTHERAPY APRIL 1992 Acinetobacter calcoaceticus Staphylococcus aureus, Escherichia coli P. aeruginosa E. eoli, Klebsiella pneumoniae Serratia marc
APRIL 1992 Acinetobacter calcoaceticus Staphylococcus aureus, Escherichia coli P. aeruginosa E. eoli, Klebsiella pneumoniae Serratia marcescens P. aeruginosa P. aeruginosa Streptococcus pyogenes Streptococcus
20 15 14.6 15.3 14.9 15.7 16.0 15.7 13.4 14.5 13.7 14.2 10 10 13 16 19 22 1 70,000 60,000 50,000 40,000 30,000 20,000 10,000 0 2,500 59,862 56,384 2,000 42,662 44,211 40,639 37,323 1,500 33,408 34,472
- 2 -
- 2 - - 3 - (1) (2) (3) (1) - 4 - ~ - 5 - (2) - 6 - (1) (1) - 7 - - 8 - (i) (ii) (iii) (ii) (iii) (ii) 10 - 9 - (3) - 10 - (3) - 11 - - 12 - (1) - 13 - - 14 - (2) - 15 - - 16 - (3) - 17 - - 18 - (4) -
2 1980 8 4 4 4 4 4 3 4 2 4 4 2 4 6 0 0 6 4 2 4 1 2 2 1 4 4 4 2 3 3 3 4 3 4 4 4 4 2 5 5 2 4 4 4 0 3 3 0 9 10 10 9 1 1
1 1979 6 24 3 4 4 4 4 3 4 4 2 3 4 4 6 0 0 6 2 4 4 4 3 0 0 3 3 3 4 3 2 4 3? 4 3 4 3 4 4 4 4 3 3 4 4 4 4 2 1 1 2 15 4 4 15 0 1 2 1980 8 4 4 4 4 4 3 4 2 4 4 2 4 6 0 0 6 4 2 4 1 2 2 1 4 4 4 2 3 3 3 4 3 4 4
I? 3 1 3 1.1?................................. 3 1.2?............................... 3 1.3!................................... 3 2 4 2.1........................................ 4 2.2.......................................
1 (1) (2)
1 2 (1) (2) (3) 3-78 - 1 (1) (2) - 79 - i) ii) iii) (3) (4) (5) (6) - 80 - (7) (8) (9) (10) 2 (1) (2) (3) (4) i) - 81 - ii) (a) (b) 3 (1) (2) - 82 - - 83 - - 84 - - 85 - - 86 - (1) (2) (3) (4) (5) (6)
好酸球性副鼻腔炎:診断ガイドライン（JESREC Study）
118 728 2015 : : JESREC Study Japanese Epidemiological Survey of Refractory Eosinophilic Chronic Rhinosinusitis Study : JESREC Study CT NSAIDs CT : JESREC Study JESREC Study 118 729 ph CTMRI Caldwell Luc
Synagis RS RSRespiratory Syncytial Virus RSBPD CHDRS RS RS BPD CHD 50mg100mg RS20138 RS Respiratory Syncytial Virus RS
RS Synagis RS RSRespiratory Syncytial Virus RSBPD CHDRS RS RS1998 7020021BPD 200510CHD 50mg100mg2012 812 RS20138 RS Respiratory Syncytial Virus RS 28 12 29 35 6 6BPD24 24CHD 24 24 28 2935 RS 12 6 RS BPD
新入_本文.smd
52 28 220 28 4 1 017-777-1511 2 2 8 2 9 8 9 47.2% 12.8% 11.5% 6.0% 4 2 (49.6%)(13.0%) (14.7%) (7.4%)(8.4%) (52.3%)(9.1%) (11.4%) (10.0%) 33.0% 23.4% 15.6% 9.6% (26.0%) (18.3%) (46.5%) (30.0%) (20.0%) 2
CHEMOTHERAPY APR Fig. 1 Chemical structure of cefotetan (CTT, YM09330)
CHEMOTHERAPY APR. 1982 Fig. 1 Chemical structure of cefotetan (CTT, YM09330) VOL.30 S-1 CHEMOTHERAPY Fig. 2 Comparison of standard curves of CTT on various test organisms by cylinder plate method Column
Fig.1 Chemical structure of BAY o 9867
Fig.1 Chemical structure of BAY o 9867 CHEMOTHERAPY 43 Table 3 Antibacterial spectrum of gram negative bacteria Medium:Heart infusion agar (Nissui) Method:Agar dilution (Streak) CHEMOTHERAPY DEC 1985
5 Armitage x 1,, x n y i = 10x i + 3 y i = log x i {x i } {y i } 1.2 n i i x ij i j y ij, z ij i j 2 1 y = a x + b ( cm) x ij (i j )
5 Armitage. x,, x n y i = 0x i + 3 y i = log x i x i y i.2 n i i x ij i j y ij, z ij i j 2 y = a x + b 2 2. ( cm) x ij (i j ) (i) x, x 2 σ 2 x,, σ 2 x,2 σ x,, σ x,2 t t x * (ii) (i) m y ij = x ij /00 y
Rinku General Medical Center
Rinku General Medical Center 4860 100 1620 Ann Intern Med. 1966; 64: 328 40 CHOP 63 1 83 J Clin Oncol. 1998; 16: 20065-69 Febrile Neutropenia IDSA(Infectious Diseases Society of America) 2002 Guidelines
1 st 2 nd Dec
1 st 2 nd Dec.2007 21 2003 2 1 st 2 nd Dec.2007 5 DC DC 3 1 st 2 nd Dec.2007 1 2 3 1 2 3 4 5 1 2 3 1 2 3 4 1 st 2 nd Dec.2007 25 17 http://www.ipss.go.jp/ 5 1 st 2 nd Dec.2007 1 1 2 1:() 6 1 st 2 nd Dec.2007
Microflora in Patients Treated with Fixed Prosthetic Appliances Supragingival Plaque Formed on the Full Cast Crown - Fabricated with Platinum Gold Cas
Microflora in Patients Treated with Fixed Prosthetic Appliances Supragingival Plaque Formed on the Full Cast Crown - Fabricated with Platinum Gold Cast Alloy- Junichi Mega, Yosizumi Murata, Masatomo Hirasawa*
36 th IChO : - 3 ( ) , G O O D L U C K final 1
36 th ICh - - 5 - - : - 3 ( ) - 169 - -, - - - - - - - G D L U C K final 1 1 1.01 2 e 4.00 3 Li 6.94 4 Be 9.01 5 B 10.81 6 C 12.01 7 N 14.01 8 16.00 9 F 19.00 10 Ne 20.18 11 Na 22.99 12 Mg 24.31 Periodic
untitled
17 5 13 1 2 1.1... 2 1.2... 2 1.3... 3 2 3 2.1... 3 2.2... 5 3 6 3.1... 6 3.2... 7 3.3 t... 7 3.4 BC a... 9 3.5... 10 4 11 1 1 θ n ˆθ. ˆθ, ˆθ, ˆθ.,, ˆθ.,.,,,. 1.1 ˆθ σ 2 = E(ˆθ E ˆθ) 2 b = E(ˆθ θ). Y 1,,Y
Streptococcus pneumoniae,streptococcus pyogenes,streptococcus agalactiae,neisseria gonorrhoeae,h.influenzae,moraxella subgenus Branhamella catarrharis
Streptococcus pneumoniae,streptococcus pyogenes,streptococcus agalactiae,neisseria gonorrhoeae,h.influenzae,moraxella subgenus Branhamella catarrharis, E.coil,Klebsiella pneumoniae,klebsiella oxytoca,proteus
日本化学療法学会雑誌第66巻第2号
173 Table 1.Detection rates of Neisseria gonorrhoeae, Chlamydia trachomatis, Mycoplasma genitalium, Ureaplasma urealyticum, Haemophilus influenzae and adenovirus from male urethritis in Urethritis No.
83
Candida sppmssa Haemophilus influenzae consolidation consolidation consolidation consolidation consolidation consolidation knuckle sign Westermark sign Hampton s hump Borchardt enteropathy-associated
Key words : candidemia, endotoxin, D-arabinitol, Candida antigen, serological examination
Key words : candidemia, endotoxin, D-arabinitol, Candida antigen, serological examination Fig. 1 The value of fungal index and D- arabinitol/creatinine. Fungal index was mesured by Endotoxin D and Endospecy
1) Stallmann, F. W., and Pipberger, H. V.: Automatic recognition of electrocardiographic waves by digital computer. Circulation Research, 9, 1138, 1961. 2) Whitemen, J. R., Gorman, P. A., Calataynd, J.
.K.C.h...C...ren
1 1, 2 4.1 3.0 5.2 3.7 2.8 4.6 3.9 3.2 4.6 0.3 0.0 0.7 0.2 0.0 0.5 0.3 0.1 0.5 3.7 2.7 4.8 3.5 2.6 4.4 3.6 2.9 4.3 0.3 0.0 0.7 0.9 0.5 1.3 0.6 0.4 0.9 0.6 0.2 1.0 0.4 0.1 0.7 0.5 0.2 0.7 5.0 3.9 6.2 5.0
CW3_A6075D02.indd
1/7 Japanese Journal of Comprehensive Rehabilitation Science (2011) Original Article Miyasaka H, Kondo I, Kato H, Takahashi C, Uematsu H, Yasui C, Tani A, Miyata M, Wada N, Teranishi T, Wada Y, Sonoda
95 life history Gramling & Carr, 2004 Erikson1963 Levinson 1986 2000 Boyd, Holmes, & Purnell, 1998 Martyn & Belli, 2002 Admi1995 96 54 2000 1 2005 1 2000 0 1 9 5 7 10 14 15 16 17 18 19 21 A 1 2000 1 8
CHEMOTHERAPY Proteus mirabilis GN-79 Escherichia coli No. 35 Proteus vulgaris GN-76 Pseudomonas aeruginosa No. 11 Escherichia coli ML-1410 RGN-823 Kle
VOL. 29 NO.8 CHEMOTHERAPY 865 CHEMOTHERAPY Proteus mirabilis GN-79 Escherichia coli No. 35 Proteus vulgaris GN-76 Pseudomonas aeruginosa No. 11 Escherichia coli ML-1410 RGN-823 Klebsiella pneumoniae GN-69
VENTANA ALK D5F3 Rabbit Monoclonal Antibody OptiView ALK D5F3
VENTANA ALK D5F3 Rabbit Monoclonal Antibody OptiView ALK D5F3 2 OptiView ALK D5F3 11 10 79.3%31% 18% 80 85NSCLC 40% 1,2 1 1018 ALK ALK 2 ALK 3 5% ALK EML4 EML4-ALK Coild-Coil ALK ALK 3,4,5 2 6 EGFR 50%
日本化学療法学会雑誌第57巻第1号
In vitro Streptococcus pneumoniae Escherichia coli in vitro Streptococcus pneumoniae Escherichia coli µs. pneumoniae E. coli µ Key words in vitrostreptococcus pneumoniae Escherichia coli Escherichia coli
coccus aureus Corynebacterium sp, Haemophilus parainfluenzae Klebsiella pneumoniae Pseudornonas aeruginosa Pseudomonas sp., Xanthomonas maltophilia, F
VOL.43 S-1 coccus aureus Corynebacterium sp, Haemophilus parainfluenzae Klebsiella pneumoniae Pseudornonas aeruginosa Pseudomonas sp., Xanthomonas maltophilia, Flavobacter- Table 1. Concentration of grepafloxacin
CHEMOTHERAPY FEB Table 1. Activity of cefpirome and others against clinical isolates
VOL.39 S-1 CHEMOTHERAPY FEB. 1981 Table 1. Activity of cefpirome and others against clinical isolates VOL.39 S-1 CHEMOTHERAPY FEB. 1991 72 M, 55.5 kg 66 F, 53 kg Chronic bronchitis Bronchopneumonia Peak
interviewer interviewee interviewer interviewee interviewer interviewee Kurt Lewin Lewin, ;, Lewin, ;, Lewin C
interviewer interviewee interviewer interviewee interviewer interviewee Kurt Lewin Lewin, ;, Lewin, ;, Lewin C Vaughn, Schumm, and Sinagub Focus group interviews in education and psychology Bellenger,
臨床神経45-1.indb
59 Case of the Issue No. 9 carpal tunnel syndrome: CTS CTS CTS CTS nerve conduction study; NCS needle electromyography; nemg NCS carpal tunnel syndrome: CTS 1 CTS 4 CTS 45 65 1 3 2 CTS CTS 1999 American
Power Transformation and Its Modifications Toshimitsu HAMASAKI, Tatsuya ISOMURA, Megu OHTAKI and Masashi GOTO Key words : identity transformation, pow
Power Transformation and Its Modifications Toshimitsu HAMASAKI, Tatsuya ISOMURA, Megu OHTAKI and Masashi GOTO Key words : identity transformation, power-normal distribution, structured data, unstructured
日本化学療法学会雑誌第56巻第1号
β β β β β Streptococcus pneumoniaehaemophilus influenzaemoraxella catarrhalismycoplasma pneumoniaechlamydia pneumoniae β Key wordsβ mys nilc laci ngis Table. Assessmentschedule Parameters Patientcharacteristics
15) Egawa, R., Sawai, T. and Mit.uhashi, S.: Jap. J. Microbiol., 11 : 173-178, 1967. 16) Tanaka, T. and Hashimoto, H., Nagai, Y. and Mitsuhashi, S.: Jap. J. Microbiol., 11: 155-162, 1967. 17) Mitsuhashi,
1) Kojima H: Culture of ejaculate for Neisseria gonorrhoeae, 1st Serually Transmitted Diseases World Congress, San Juan, 11. 19, 1981. 9) Kojima H, Mori C: Clinical studies on Conococcal and Chlamydial
(ABPC), Carbenicillin (CBPC), Surbenicillin (SBPC), Piperacillin (PIPC), Cephalexin (CEX), Cefaclor (CCL), Cephalothin (CET), Cefazolin (CEZ), Cefotia
Key words: Blood culture, Trend of bacterial isolation, Increasing of staphylococcus, Use of new cephems (ABPC), Carbenicillin (CBPC), Surbenicillin (SBPC), Piperacillin (PIPC), Cephalexin (CEX), Cefaclor